Statistik Asas
| LEI | 5493002KU8ACFTSMC935 |
| CIK | 1472091 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to EA Series Trust - MRBL Enhanced Equity ETF
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount to be registered Proposed maximum offering price per unit Maximum Aggregate Offering Price Fee Rate Amount of registration fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
PDS Biotechnology Corporation Dated as of [●] TABLE OF CONTENTS Exhibit 4.3 PDS Biotechnology Corporation INDENTURE Dated as of [●] [●] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally 5 SECTION 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 5 SECTION 2.03. Form of Trust |
|
| August 25, 2025 |
Exhibit 99.1 PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., August 25, 2025 - PDS Biotechnology Corporati |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 25, 2025 |
Exhibit 99.1 Precision Designed Science for Cancer Patients NASDAQ: PDSB August 2025 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Co |
|
| August 13, 2025 |
Exhibit 10.2 AMENDMENT AGREEMENT This Amendment Agreement (this “Agreement”) is entered into as of May 20, 2025, by and among JGB Capital, L.P., JGB Partners, L.P., JGB Capital Offshore Ltd. and Alto Opportunity Master Fund SPC – Segregated Master Portfolio B (collectively, the “Buyers”), PDS Biotechnology Corporation, a Delaware corporation (the “Company”) and JGB Collateral LLC, as Collateral Ag |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 13, 2025 |
Exhibit 10.7 PDS BIOTECHNOLOGY CORPORATION RESTRICTED STOCK UNITS NOTICE UNDER THE PDS BIOTECHNOLOGY CORPORATION THIRD AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of PDS Biotechnology Corporation, a Delaware corporation (the “Company”), that have been granted to you pursuan |
|
| August 13, 2025 |
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update Exhibit 99.1 PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., August 13, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunother |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnol |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 10, 2025 |
Exhibit 99.1 PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort Study Demonstrates Promising Response Rate, Triggering Enrollment Expansion Under Simon Two-Stage Design PRINCETON, N.J., July 10, 2025 - PDS Biotechnology Corporation |
|
| June 25, 2025 |
Exhibit 99.1 Addressing the Growing Incidence of HPV16-Related Cancers NASDAQ: PDSB June 2025 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amen |
|
| June 25, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 11, 2025 |
AMENDMENT TO THE THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INVENTIVE PLAN Exhibit 10.1 AMENDMENT TO THE THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INVENTIVE PLAN WHEREAS, PDS Biotechnology Corporation, Inc. (the “Company”) maintains the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Plan”); and WHEREAS, Section 9.1 of the Plan provides that the Plan may be amended from time to time; and WHEREAS, the Co |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2025 Date of Report (Date of earliest event reported) PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 001-37568 26-4231384 (State or other jurisdiction of incorporation) (Commiss |
|
| June 6, 2025 |
PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540 PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540 June 6, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 2, 2025 |
Exhibit 99.1 PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial |
|
| May 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities* Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| May 27, 2025 |
As filed with the Securities and Exchange Commission on May 27, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 27, 2025 Registration No. |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 22, 2025 |
Exhibit 99.1 PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 i |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno |
|
| May 14, 2025 |
Exhibit 99.1 PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 - PDS Biotechnology Corporatio |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 8, 2025 |
Exhibit 99.1 PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting Infectimune® studies funded by and performed by investigators at the National Institute of Allergy and Infectious Diseases (NIAID)’s Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP) PRINCETON, N.J., May 8, 2025 - PDS Biotechnology Co |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 2, 2025 |
COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 2, 2025 |
SENIOR SECURED CONVERTIBLE DEBENTURE DUE [__], 2028 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 2, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 30, 2025, between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities P |
|
| May 2, 2025 |
Exhibit 10.4 SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of April 30, 2025 (this “Guaranty”), and made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of JGB Collateral LLC, a Delaware limited liability company (the “Collateral Agent”), on behalf of holders those Senior Secured Convertible Debe |
|
| May 2, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 30, 2025, between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively, the “Buyers”), and JGB Collateral LLC, a Delaware limited liability |
|
| May 2, 2025 |
Exhibit 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of April 30, 2025 (this “Agreement”), is made by PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and the Subsidiaries of the Company party hereto from time to time (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) in favor of the JGB Collateral LLC, a Delaware limited liability |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy |
|
| April 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnology Corporation |
|
| March 27, 2025 |
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update Exhibit 99.1 PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stag |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 13, 2025 |
Exhibit 99.1 PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations |
|
| March 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 7, 2025 |
Exhibit 99.1 PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer First-ever HPV16-positive head and neck cancer Phase 3 clinical trial PRINCETON, N.J., March 7, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 28, 2025 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 26, 2025 PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540 Attn: Chief Executive Officer Dear Dr. Bedu-Addo: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”), that the Placement Agent |
|
| February 28, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2025 between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| February 28, 2025 |
COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Exhibit 4.2 COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Warrant Shares: Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [th |
|
| February 28, 2025 |
Exhibit 99.1 PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the Warrants PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immuno |
|
| February 28, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PDS BIOTECHNOLOGY CORPORATION Warrant Shares: Issue Date: [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo |
|
| February 28, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267041 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2022) 6,396,787 Shares of Common Stock Pre-Funded Warrants to Purchase up to 933,334 Shares of Common Stock Warrants to Purchase up to 7,330,121 Shares of Common Stock We are offering on a “best efforts” basis 6,396,787 shares (the “Shares”) of our common stock, |
|
| February 26, 2025 |
Exhibit 99.1 PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibit |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 24, 2025 |
Exhibit 99.1 PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT was associated with greater and earlier clearance of blood- |
|
| February 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 5, 2025 |
Exhibit 99.1 PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma FDA-cleared amended trial design; First site initiation expected Q1 2025 PRINCETON, N.J., February 5, 2025 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunothe |
|
| February 5, 2025 |
Exhibit 99.2 Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB February 2025 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Secu |
|
| November 14, 2024 |
Exhibit 99.2 1 © 2024 PDS Biotechnology. All Rights Reserved. Transforming How the Immune System Targets and Fights Cancer to Promote Survival Precision Designed Science For Immunotherapy NASDAQ: PDSB November 2024 Forward-Looking Statements 2 This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biote |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 14, 2024 |
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results Conference call and webcast today at 8:30 a.m. Eastern Time PRINCETON, N.J., November 14, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the d |
|
| October 2, 2024 |
Exhibit 99.2 IMMUNOCERV Phase II Trial Combining the HPV-specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer Adam J Grippin1, Kyoko Yoshida-Court1, Madison O’Hara1, Olsi Gjyshi2, Geena Mathew1, Maliah Domingo1, Lilie Lin1, Anuja Jhingran1, Melissa Joyner1, Tatiana Cisneros Napravnik1, Kathleen Schmeler1, Michael Hernandez1, Erica Lynn1, Aaron |
|
| October 2, 2024 |
Exhibit 99.1 PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| September 16, 2024 |
Exhibit 99.1 Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB September 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Sec |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| September 16, 2024 |
Exhibit 99.1 PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical trial planned to begin this year PRINCETON, N.J., September 16, 2024 - PDS Biotechno |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 13, 2024 |
Exhibit 10.1 Execution Version PDS BIOTECHNOLOGY CORPORATION Common Stock (par value $0.00033 per share) Amended and Restated At Market Issuance Sales Agreement August 13, 2024 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: PDS Biotechnology Corporation, a Delaware corporation (the “Compan |
|
| August 13, 2024 |
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results PRINCETON, N.J., August 13, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business u |
|
| August 13, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267041 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2022) Up to $50,000,000 Common Stock We have entered into an amended and restated At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC (each an “Agent” and collectively the “Agents”) relating to |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnol |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 8, 2024 |
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting Exhibit 99.1 PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting PRINCETON, N.J., August 8, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that upd |
|
| August 7, 2024 |
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024 Exhibit 99.1 PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024 PRINCETON, N.J., August 7, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will r |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 5, 2024 |
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024 Exhibit 99.1 PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024 PRINCETON, N.J., August 5, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that an abstract pre |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 1, 2024 |
Exhibit 99.1 PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., August 1, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on tr |
|
| August 1, 2024 |
Exhibit 99.2 Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB August 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securi |
|
| June 24, 2024 |
Exhibit 10.1 CERTIFICATE OF AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PDS BIOTECHNOLOGY CORPORATION PDS Biotechnology Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY THAT: FIRST: The name of the Corporation is PDS Biotechnology Corporation. SECON |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2024 Date of Report (Date of earliest event reported) PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 001-37568 26-4231384 (State or other jurisdiction of incorporation) (Commiss |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 12, 2024 |
Exhibit 99.1 PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 - PDS Bio |
|
| June 12, 2024 |
Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB June 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 15, 2024 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective May 1, 2024 (the “Effective Date”), by and between Stephan F. Toutain, MS, MBA (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desire |
|
| May 15, 2024 |
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results Exhibit 99.1 PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15, 2024 - PDS Biotechnology Corporati |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 10, 2024 |
Exhibit 99.1 PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer 30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 9, 2024 - PDS Biotechnology Corporation (Nasdaq |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 8, 2024 |
Exhibit 99.1 Transforming How the Immune System Targets and Fights Cancer to Promote Survival © 2024 PDS Biotechnology. All Rights Reserved. NASDAQ: PDSB May 2024 Precision Designed Science For Immunotherapy Forward-Looking Statement This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 7934, as amended, |
|
| May 2, 2024 |
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer Exhibit 99.1 PDS Biotech Appoints Stephan Toutain as Chief Operating Officer Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., May 2, 2024 - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease va |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy |
|
| April 18, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 28, 2024 |
Calculation of Filing Fee Tables Form S-8 (Form Type) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnology Corporation |
|
| March 28, 2024 |
PDS Biotechnology Corporation Policy on Insider Trading Exhibit 19 Title: Insider Trading Policy SOP Number: LEG-POL-002 Version Number: V00 Supersedes: Initial Effective Date: Next Review Due By: October 2026 PDS Biotechnology Corporation Policy on Insider Trading 1. |
|
| March 28, 2024 |
Subsidiaries of PDS Biotechnology Corporation Exhibit 21.1 Subsidiaries of PDS Biotechnology Corporation Name State or other Jurisdiction of Incorporation or Organization PDS Operating Corporation Delaware |
|
| March 28, 2024 |
Exhibit 97 PDS BIOTECHNOLOGY CORPORATION POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION (Adopted October 19, 2023) 1. |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.27 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective January 16, 2024 (the “Effective Date”), by and between Kirk V. Shepard, MD (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desires |
|
| March 28, 2024 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.26 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into effective December 4, 2023 (the “Effective Date”), by and between Lars Robert Boesgaard (“Executive”) and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Each of the Company and Executive is a “Party” and, collectively, they are the “Parties.” The Company desire |
|
| March 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 27, 2024 |
PDS Biotech Announces Clinical Strategy Update and Reports Exhibit 99.1 PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) |
|
| March 27, 2024 |
Exhibit 99.2 Transforming How the Immune System Targets and Fights Cancer NASDAQ: PDSB March 2024 Forward-Looking Statement This communication contains forward-looking statements (including within the meaning of Section 27E of the United States Securities Exchange Act of 7934, as amended, and Section 27A of the United States Securities Act of 7933, as amended) concerning PDS Biotechnology Corporat |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 13, 2024 |
Exhibit 99.1 PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and use of Infectimune® based influenza vaccines gr |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| January 22, 2024 |
Exhibit 99.1 PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company PRINCETON, N.J., January 22, 2024 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) |
|
| January 22, 2024 |
Exhibit 10.1 PDS BIOTECHNOLOGY CORPORATION 2019 INDUCEMENT PLAN Amended on January 22, 2024 SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the PDS Biotechnology Corporation 2019 Inducement Plan (the “Plan”). The purpose of the Plan is to provide non-qualified stock options to individuals not previously employees or Non-Employee Directors of PDS Biotechnology Company (t |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| December 4, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB December 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporatio |
|
| November 28, 2023 |
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer Exhibit 99.1 PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer PRINCETON, N.J., November 28, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating pl |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 14, 2023 |
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update • Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI1 • Announced 2-year overall survival rate of 74% in VERSATILE-002 Phase 2 trial |
|
| November 14, 2023 |
As filed with the Securities and Exchange Commission on November 14, 2023 As filed with the Securities and Exchange Commission on November 14, 2023 Registration No. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biote |
|
| November 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 9, 2023 |
Exhibit 99.1 PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101 Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which shows 75% Survival of ICI Naïve Patients at 36 Months • 75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months • |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 23, 2023 |
Exhibit 99.1 PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO ● Combination of PDS0101 and KEYTRUDA® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity ● Lowered CD8 T cells in peripheral blood after treatment align with previously repo |
|
| October 11, 2023 |
Exhibit 99.1 PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer ● First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301). ● Decrease in prostate |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 3, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 3, 2023 |
Exhibit 99.1 PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) • Interim VERSATILE-002 data for the first-line treatment of recurrent or metastatic head and neck cancer patients who were immune checkpoint inhibitor (ICI) naïve; published 24-month survival |
|
| October 3, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB October 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 3, 2023 |
Exhibit 99.1 PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable NASDAQ: PDSB October 3, 2023 Forward Looking Statements Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Certain information in this presentation may include forward-looking sta |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 2, 2023 |
Exhibit 99.1 PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) ● Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally advanced cervical cancer in the IMMUNOCERV Phase 2 clinical trial and patients receiving standard of care (SOC) treatment ● Patients treated with PDS0101 had greater |
|
| September 20, 2023 |
Exhibit 99.1 PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies ● PDS0202 (Infectimune® + COBRA influenza antigens) vaccination also prevented illness/weight loss ● Vaccine protected against replication of the virus in the lungs of ferrets after challenge with the H1N1 virus ● Data from Cleveland Clinic’s Ted Ross Lab presented at the 9 |
|
| September 20, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| September 11, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB September 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporati |
|
| September 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| September 8, 2023 |
Exhibit 99.1 PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference PRINCETON, N.J., September 6, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Co |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 18, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB August 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation |
|
| August 17, 2023 |
Exhibit 99.1 PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting Study evaluates the effect of combining PDS0101 with standard of care on levels of circulating HPV viral DNA in cervical cancer patients and impact on disease status and clearance Princeton, N.J., A |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 14, 2023 |
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update ● Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023 ● Biomarker data from VERSATILE-002 to be presented at ESMO 2023 ● Company to host conference call and webcast today at 8:00 AM EDT PRINCETON, N |
|
| August 14, 2023 |
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial Exhibit 99.1 PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in the fourth quarter of 2023 Princeton, NJ, August 14, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB) |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnol |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| August 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 25, 2023 |
Exhibit 99.1 PDS Biotech to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023 Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in subjects receiving PDS0101 and KEYTRUDA® for recurrent or metastatic HPV16-positive head and neck cancer Florham Park, NJ, July 25, 2023 |
|
| July 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2023 Date of Report (Date of earliest event reported) PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 001-37568 26-4231384 (State or other jurisdiction of incorporation) (Commiss |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 17, 2023 |
Exhibit 99.1 PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023 First clinical study of immunocytokine with docetaxel in prostate cancer patients Florham Park, NJ, July 17, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy compa |
|
| July 17, 2023 |
Exhibit 10.1 THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INCENTIVE PLAN Adopted by the Board of Directors on May 19, 2023 THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION 2014 EQUITY INCENTIVE PLAN Section 1. Purpose of the Plan. The purpose of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (formerly known as the Second Amen |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| July 11, 2023 |
Exhibit 99.1 PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301 • Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in Canada • PDS Biotech’s proprietary combination of Versamune® based PDS0101 and PDS0301 with an immune checkpoint inhibitor resulted in 21 months median overall survival in advanced HPV-pos |
|
| June 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 14, 2023 |
Exhibit 99.1 PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer • 14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed objective response • Efficacy and |
|
| June 14, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB June 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (t |
|
| June 2, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| June 1, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (th |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 25, 2023 |
Exhibit 99.1 Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (th |
|
| May 25, 2023 |
Exhibit 99.1 PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients • Interim data being presented at ASCO 2023 Annual Meeting • Demonstrated median progression-free survival (PFS) of 10.4 months • Demonstrated 12-month overall survival (OS) rate of 87.1% • A disease control rate (di |
|
| May 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 18, 2023 |
Exhibit 99.1 PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023 FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a |
|
| May 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| May 17, 2023 |
Exhibit 99.1 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | May 2023 2 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechno |
|
| May 15, 2023 |
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage company developing a growing pip |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotec |
|
| April 27, 2023 |
Exhibit 99.1 PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients Abstract selected as featured poster to be reviewed by expert panel in the Head and Neck Cancer discussion session FLORHAM PARK, N.J., April 27, 2023 - PDS Biotechnology Corporation (N |
|
| April 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 27, 2023 |
Exhibit 99.1 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | April 2023 2 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnolo |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 24, 2023 |
Exhibit 99.1 PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease announced the Compan |
|
| April 21, 2023 |
Exhibit 99.1 Interleukin-12 (IL-12) KOL Roundtable NASDAQ: PDSB | April 21, 2023 Forward Looking Statements Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology |
|
| April 21, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 12, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 12, 2023 |
PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023 Exhibit 99.1 PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023 FLORHAM PARK, N.J., April 12, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced it will host a Key Opinion Leader (KOL) Roundtable on Interleuk |
|
| April 6, 2023 |
Exhibit 99.1 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | April 2023 2 This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Compan |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| April 3, 2023 |
Exhibit 99.1 PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023 Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasd |
|
| March 30, 2023 |
Exhibit 99.1 PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023 Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation (Nasd |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 28, 2023 |
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results Exhibit 99.1 PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results ● Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor ● 100% (9/9) clinical response (>60% tumor shrinkage at mid-point evaluation) in IMMUNOCERV trial for high-risk cervical cancer patie |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biotechnology Corporation |
|
| March 28, 2023 |
Exhibit 10.9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LICENSE AGREEMENT dated December 30, 2022 by and between Merck KGaA, Darmstadt, Germany and PDS Biotechnology Corporation TABLE OF CONTENTS ARTICLE 1 DEFINITION |
|
| March 28, 2023 |
Subsidiaries of PDS Biotechnology Corporation Exhibit 21.1 Subsidiaries of PDS Biotechnology Corporation Name State or other Jurisdiction of Incorporation or Organization PDS Operating Corporation Delaware |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 14, 2023 |
Exhibit 99.1 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | March 2023 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| March 1, 2023 |
Exhibit 99.1 PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal National Cancer Institute (NCI)-led research of PDS0301, a novel investigational tumor-targeting IL-12 fusion protein, shows dose-dependent, immune responses and association with improved clinical outcomes FLORHAM PARK, N |
|
| March 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 27, 2023 |
Good-Bye! (Leaving the SEC Website) This page is temporarily unavailable. Exhibit 99.1 PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer FLORHAM PARK, N.J., Feb. 27, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunoth |
|
| February 16, 2023 |
Exhibit 99.1 PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™ Infectimune™ (R-DOTAP) nanoparticles significantly enhance cytokine-inducing, CD4 T cell responses compared to leading commercial adjuvants being used in approved vaccines FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) - PDS Biotechnology Corporation |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 8, 2023 |
EX-99.1 2 brhc10047772ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses Infectimune™ induced neutralizing antibody and robust T cell responses completely protecting animals against sickness after lethal challenge with live SARS-CoV-2 or |
|
| February 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| February 6, 2023 |
EX-99.1 2 brhc10047617ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” highlights data generated from VERSATILE-002 Phase 2 study FLORHAM PARK, N.J., Feb. 06, 2023 (GLOB |
|
| January 19, 2023 |
Exhibit 99.1 Precision Designed Science For Immunotherapy Oncology Platforms and Clinical Data Summary NASDAQ: PDSB | January 2023 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) con |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| January 3, 2023 |
Exhibit 10.1 Execution Version SHARE TRANSFER AGREEMENT This Share Transfer Agreement (this ?Agreement?) is made effective as of December 30, 2022 (the ?Effective Date?), by and between PDS Biotechnology Corporation, a Delaware corporation (the ?Company?), and Merck KGaA, Darmstadt, Germany, a corporation with general partners organized under German law (the ?Investor?). WHEREAS, simultaneously wi |
|
| January 3, 2023 |
EX-99.2 4 brhc10046080ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | January 2023 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act o |
|
| January 3, 2023 |
Exhibit 99.1 PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune? platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at 8:00 AM EST FLORHAM PARK, N.J., January 3, 202 |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| December 28, 2022 |
Exhibit 99.1 PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2 clinical trial of PDS0101 triple combination Florham Pa |
|
| December 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| December 15, 2022 |
Exhibit 99.1 PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer VERSATILE-002 Phase 2 study investigating PDS0101 in combination with Merck’s KEYTRUDA® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naïve patients Florham Park, NJ, December 15, 2022 - PDS |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| December 12, 2022 |
Exhibit 99.1 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | December 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnol |
|
| November 21, 2022 |
Exhibit 99.1 PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform Dr. Siva Gandhapudi, Director of Immunology Product Development, to present on development of a univ |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 14, 2022 |
VENTURE LOAN AND SECURITY AGREEMENT Exhibit 10.2 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]” VENTURE LOAN AND SECURITY AGREEMENT Dated as of August 24, 2022 by and among HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware co |
|
| November 14, 2022 |
Exhibit 99.2 PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: • 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation) • 89% (8/9) had no evidence of disease (complete response) on day 170 Data Prese |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37568 PDS Biote |
|
| November 14, 2022 |
PDS BIOTECHNOLOGY CORPORATION WARRANT TO PURCHASE SHARES OF COMMON STOCK (Loan [A/B/C/D/E/F]) Exhibit 10.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 14, 2022 |
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update • Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC 2022 • Announced successful end-of-Phase 2 meeting with FDA for VERSATILE-002, allowing preparation for |
|
| November 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 7, 2022 |
Exhibit 99.1 PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022) Patients with high-risk, locally advanced cervical cancer on IMMUNOCERV demonstrated increased tumor-infiltrating polyfunctional CD8+ (killer) T cells, and 1-year overall survival of 100% Data from study across several checkpoint inhibitor |
|
| October 27, 2022 |
Head and Neck Cancer KOL Roundtable NASDAQ: PDSB | October 26, 2022 Exhibit 99.1 Head and Neck Cancer KOL Roundtable NASDAQ: PDSB | October 26, 2022 Forward Looking Statements Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology |
|
| October 27, 2022 |
Exhibit 99.1 PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA?, presents interim data from the study Combination shows potential to achieve oncologists? goals of improved clinical outcomes with improved quality of life and survival in the treatment of recurrent/metastatic |
|
| October 27, 2022 |
Exhibit 99.2 Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | October 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnolo |
|
| October 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
|
| October 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 PDS BIOTECHNOLOGY CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-37568 26-4231384 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I. |
